|43.90|| +0.24 / +0.55%|
Mylan N.V., is a pharmaceutical company which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceutical products. It operates through the following businesses: Generic Products, Rx Products, Active Pharmaceutical Ingredients, and Access Channels. The Generic Products business provides therapeutic categories, dosage forms and delivery system to help patients. The Rx Products business develops, manufacture and sells prescription medicines to help patients and physicians manage respiratory diseases, severe allergic reactions and psychiatric disorders. The Active Pharmaceutical Ingredients business produces API, the ingredients responsible for medicine's therapeutic effects, and antiretrovirals, the medicines for human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). The Access Channels business provides access to medicines. The company was founded on July 7, 2014 and is headquartered in Potters Bar, United Kingdom.
|Heather M. Bresch||Chief Executive Officer & Executive Director|
|Rajiv Malik||President & Executive Director|
|John D. Sheehan||Executive VP, Chief Financial & Accounting Officer|
|Kris King||Vice President-Global Investor Relations|
|Bradley L. Wideman||General Counsel|